Covid-19 vaccine research stock images , in Zagreb, Croatia, November 12, 2020. Pfizer Inc. (NYSE: PFE) and BioNTech SE(Nasdaq: BNTX) announced their mRNA-based vaccine candidate, BNT162b2, against SARS-CoV-2 has demonstrated evidence of efficacy against COVID-19 in participants without prior evidence of SARS-CoV-2 infection, based on the first interim efficacy analysis conducted on November 8, 2020 by an external, independent Data Monitoring Committee (DMC) from the Phase 3 clinical study.The case split between vaccinated individuals and those who received the placebo indicates a vaccine eff
Image details
Contributor:
Pixsell / Alamy Stock PhotoImage ID:
2KXJJFEFile size:
29 MB (1.6 MB Compressed download)Releases:
Model - no | Property - noDo I need a release?Dimensions:
4000 x 2535 px | 33.9 x 21.5 cm | 13.3 x 8.5 inches | 300dpiDate taken:
12 November 2020Photographer:
Zeljko Lukunic/PIXSELLMore information:
This image could have imperfections as it’s either historical or reportage.
Covid-19 vaccine research stock images , in Zagreb, Croatia, November 12, 2020. Pfizer Inc. (NYSE: PFE) and BioNTech SE(Nasdaq: BNTX) announced their mRNA-based vaccine candidate, BNT162b2, against SARS-CoV-2 has demonstrated evidence of efficacy against COVID-19 in participants without prior evidence of SARS-CoV-2 infection, based on the first interim efficacy analysis conducted on November 8, 2020 by an external, independent Data Monitoring Committee (DMC) from the Phase 3 clinical study.The case split between vaccinated individuals and those who received the placebo indicates a vaccine efficacy rate above 90%, at 7 days after the second dose. This means that protection is achieved 28 days after the initiation of the vaccination, which consists of a 2-dose schedule. As the study continues, the final vaccine efficacy percentage may vary. Photo: Zeljko Lukunic/PIXSELL